Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 16/20 | 0.54 |
| ▸ | GRK2 | P25098 | 15/20 | 0.54 |
| ▸ | GRK3 | P35626 | 2/20 | 0.50 |
| ▸ | PRKCA | P17252 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GRK5 | P34947 | 1/20 | 0.46 |
| ▸ | GRK7 | Q8WTQ7 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4789113 | 0.86 | ROCK2 (0.55) | ROCK2GRK2GRK3PRKCALMNA | |
| SCHEMBL14736425 | 0.86 | LMNA (0.63) | ROCK2GRK2GRK3PRKCALMNA | |
| SCHEMBL14736428 | 0.82 | SMN1; SMN2 (0.51) | LMNAPDE10A | |
| SCHEMBL4788582 | 0.79 | ROCK2 (0.62) | ROCK2GRK2GRK3PRKCAGRK5 | |
| SCHEMBL4789370 | 0.79 | LMNA (0.78) | ROCK2GRK2GRK3PRKCALMNA | |
| SCHEMBL4789632 | 0.78 | ROCK2 (0.56) | ROCK2GRK2PDE10A | |
| Hydrochloric Acid SCHEMBL4789635 | 0.77 | ROCK2 (0.55) | ROCK2GRK2PDE10A | |
| Bromide SCHEMBL4788732 | 0.77 | ROCK2 (0.55) | ROCK2GRK2PDE10A | |
| SCHEMBL7910285 | 0.76 | ROCK2 (0.56) | ROCK2GRK2PDE10A | |
| Hydrochloric Acid SCHEMBL14736164 | 0.74 | ROCK2 (0.55) | ROCK2GRK2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301736-B1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2025-10-08 | — | — | EP | claimed |
| EP-4155296-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | Lead Discovery Center GmbH (DE) | 2023-03-29 | — | — | EP | claimed |
| US-8772510-B2 | PDE10 modulators | HOFFMANN-LA ROCHE INC. (US) | 2014-07-08 | — | — | US | claimed |
| US-20130059833-A1 | PDE10 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | US | claimed |
| EP-4301736-B1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2025-10-08 | — | — | EP | disclosed |
| US-20240415819-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | QLi5 Therapeutics AG (DE) | 2024-12-19 | — | — | US | disclosed |
| EP-4155296-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | Lead Discovery Center GmbH (DE) | 2023-03-29 | — | — | EP | disclosed |
| EP-2753604-B1 | PDE10 MODULATORS | HOFFMANN LA ROCHE (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-8772510-B2 | PDE10 modulators | HOFFMANN-LA ROCHE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-2574607-A1 | PDE10 modulators | F. Hoffmann-La Roche AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| WO-2013034506-A1 | PDE10 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-14 | — | — | WO | disclosed |
| US-20130059833-A1 | PDE10 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | US | disclosed |
| US-20060019952-A1 | Anti-viral therapeutics | ELIXIR PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059833-A1 | PDE10 MODULATORS | PDE10A, PDE5A, PDE2A | ROCK2 76/4885GRK2 288/4885GRK3 237/4885 |
| US-20060019952-A1 | Anti-viral therapeutics | CD4, MAVS, HAVCR2 | ROCK2 3528/4885GRK2 4500/4885GRK3 4057/4885 |
| US-20240415819-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | PSMB5, PSMA5, PSMB1 | ROCK2 4793/4885GRK2 4463/4885GRK3 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.